• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For April 27, 2022

    4/27/22 10:02:19 AM ET
    $ACC
    $ACM
    $AFIB
    $APPN
    Real Estate Investment Trusts
    Real Estate
    Military/Government/Technical
    Consumer Discretionary
    Get the next $ACC alert in real time by email

     

    Upgrades

    • BTIG upgraded the previous rating for Acutus Medical Inc (NASDAQ:AFIB) from Neutral to Buy. In the fourth quarter, Acutus Medical showed an EPS of $1.00, compared to $0.89 from the year-ago quarter. The current stock performance of Acutus Medical shows a 52-week-high of $18.00 and a 52-week-low of $0.76. Moreover, at the end of the last trading period, the closing price was at $0.80.
    • For Franklin Electric Co Inc (NASDAQ:FELE), Seaport Global upgraded the previous rating of Neutral to Buy. Franklin Electric earned $0.64 in the first quarter, compared to $0.59 in the year-ago quarter. At the moment, the stock has a 52-week-high of $96.95 and a 52-week-low of $68.27. Franklin Electric closed at $68.28 at the end of the last trading period.
    • B of A Securities upgraded the previous rating for Robert Half International Inc (NYSE:RHI) from Neutral to Buy. For the first quarter, Robert Half International had an EPS of $1.52, compared to year-ago quarter EPS of $0.98. The stock has a 52-week-high of $125.77 and a 52-week-low of $83.46. At the end of the last trading period, Robert Half International closed at $109.36.
    • According to JP Morgan, the prior rating for Avery Dennison Corp (NYSE:AVY) was changed from Neutral to Overweight. Avery Dennison earned $2.40 in the first quarter, compared to $2.40 in the year-ago quarter. At the moment, the stock has a 52-week-high of $229.24 and a 52-week-low of $156.51. Avery Dennison closed at $174.22 at the end of the last trading period.
    • For Halliburton Co (NYSE:HAL), HSBC upgraded the previous rating of Hold to Buy. For the first quarter, Halliburton had an EPS of $0.35, compared to year-ago quarter EPS of $0.19. The current stock performance of Halliburton shows a 52-week-high of $42.60 and a 52-week-low of $17.82. Moreover, at the end of the last trading period, the closing price was at $35.12.
    • HSBC upgraded the previous rating for Schlumberger Ltd (NYSE:SLB) from Hold to Buy. For the first quarter, Schlumberger had an EPS of $0.34, compared to year-ago quarter EPS of $0.21. The stock has a 52-week-high of $46.27 and a 52-week-low of $25.65. At the end of the last trading period, Schlumberger closed at $39.54.
    • For Brookfield Asset Management Inc (NYSE:BAM), Credit Suisse upgraded the previous rating of Neutral to Outperform. In the fourth quarter, Brookfield Asset Mgmt showed an EPS of $0.66, compared to $0.40 from the year-ago quarter. At the moment, the stock has a 52-week-high of $62.47 and a 52-week-low of $44.66. Brookfield Asset Mgmt closed at $49.74 at the end of the last trading period.
    • JP Morgan upgraded the previous rating for Ecolab Inc (NYSE:ECL) from Neutral to Overweight. Ecolab earned $0.82 in the first quarter, compared to $0.81 in the year-ago quarter. The stock has a 52-week-high of $238.93 and a 52-week-low of $154.85. At the end of the last trading period, Ecolab closed at $168.47.

    See all analyst ratings upgrades.

     

    Downgrades

    • For JetBlue Airways Corp (NASDAQ:JBLU), JP Morgan downgraded the previous rating of Overweight to Underweight. JetBlue Airways earned $0.80 in the first quarter, compared to $1.48 in the year-ago quarter. At the moment, the stock has a 52-week-high of $20.89 and a 52-week-low of $11.37. JetBlue Airways closed at $11.57 at the end of the last trading period.
    • B of A Securities downgraded the previous rating for Carter's Inc (NYSE:CRI) from Buy to Underperform. In the fourth quarter, Carter's showed an EPS of $2.31, compared to $2.46 from the year-ago quarter. The current stock performance of Carter's shows a 52-week-high of $116.92 and a 52-week-low of $84.41. Moreover, at the end of the last trading period, the closing price was at $86.58.
    • According to Raymond James, the prior rating for SkyWest Inc (NASDAQ:SKYW) was changed from Outperform to Market Perform. For the fourth quarter, SkyWest had an EPS of $0.09, compared to year-ago quarter EPS of $0.93. The stock has a 52-week-high of $53.50 and a 52-week-low of $22.78. At the end of the last trading period, SkyWest closed at $29.69.
    • JP Morgan downgraded the previous rating for Bank of New York Mellon Corp (NYSE:BK) from Overweight to Neutral. Bank of New York Mellon earned $0.86 in the first quarter, compared to $0.97 in the year-ago quarter. At the moment, the stock has a 52-week-high of $64.63 and a 52-week-low of $43.14. Bank of New York Mellon closed at $43.26 at the end of the last trading period.
    • According to Piper Sandler, the prior rating for Capital One Financial Corp (NYSE:COF) was changed from Overweight to Neutral. In the first quarter, Capital One Financial showed an EPS of $5.62, compared to $7.03 from the year-ago quarter. The current stock performance of Capital One Financial shows a 52-week-high of $177.95 and a 52-week-low of $122.43. Moreover, at the end of the last trading period, the closing price was at $132.23.
    • For PotlatchDeltic Corp (NASDAQ:PCH), RBC Capital downgraded the previous rating of Outperform to Sector Perform. For the first quarter, PotlatchDeltic had an EPS of $2.50, compared to year-ago quarter EPS of $1.94. The stock has a 52-week-high of $65.67 and a 52-week-low of $48.82. At the end of the last trading period, PotlatchDeltic closed at $53.75.

    See all analyst ratings downgrades.

     

    Initiations

    • With a Equal-Weight rating, Barclays initiated coverage on Warner Bros.Discovery Inc (NASDAQ:WBD). The price target seems to have been set at $24.00 for Warner Bros.Discovery. The stock has a 52-week-high of $27.50 and a 52-week-low of $19.63. At the end of the last trading period, Warner Bros.Discovery closed at $19.83.
    • With a Buy rating, Small Cap Consumer Research initiated coverage on Express, Inc. (NYSE:EXPR). The price target seems to have been set at $5.50 for Express. In the fourth quarter, Express showed an EPS of $0.11, compared to $0.66 from the year-ago quarter. The current stock performance of Express shows a 52-week-high of $8.67 and a 52-week-low of $2.74. Moreover, at the end of the last trading period, the closing price was at $3.21.
    • HC Wainwright & Co. initiated coverage on Longboard Pharmaceuticals Inc (NASDAQ:LBPH) with a Buy rating. The price target for Longboard Pharmaceuticals is set to $25.00. For the first quarter, Longboard Pharmaceuticals had an EPS of $0.52, compared to year-ago quarter EPS of $0.84. The current stock performance of Longboard Pharmaceuticals shows a 52-week-high of $18.50 and a 52-week-low of $3.90. Moreover, at the end of the last trading period, the closing price was at $4.80.
    • RBC Capital initiated coverage on AECOM (NYSE:ACM) with an Outperform rating. The price target for AECOM is set to $91.00. In the first quarter, AECOM showed an EPS of $0.89, compared to $0.62 from the year-ago quarter. At the moment, the stock has a 52-week-high of $79.97 and a 52-week-low of $58.36. AECOM closed at $71.17 at the end of the last trading period.
    • With an Outperform rating, RBC Capital initiated coverage on Jacobs Engineering Group Inc (NYSE:J). The price target seems to have been set at $173.00 for Jacobs Engineering Group. Jacobs Engineering Group earned $1.56 in the first quarter, compared to $1.41 in the year-ago quarter. The current stock performance of Jacobs Engineering Group shows a 52-week-high of $150.32 and a 52-week-low of $114.11. Moreover, at the end of the last trading period, the closing price was at $137.83.
    • Goldman Sachs initiated coverage on Organon & Co (NYSE:OGN) with a Buy rating. The price target for Organon is set to $40.00. The current stock performance of Organon shows a 52-week-high of $39.48 and a 52-week-low of $27.25. Moreover, at the end of the last trading period, the closing price was at $31.66.
    • With a Buy rating, Goldman Sachs initiated coverage on Royalty Pharma PLC (NASDAQ:RPRX). The price target seems to have been set at $56.00 for Royalty Pharma. For the fourth quarter, Royalty Pharma had an EPS of $0.80, compared to year-ago quarter EPS of $0.27. The current stock performance of Royalty Pharma shows a 52-week-high of $47.10 and a 52-week-low of $34.86. Moreover, at the end of the last trading period, the closing price was at $41.83.
    • Goldman Sachs initiated coverage on WalkMe Ltd (NASDAQ:WKME) with a Buy rating. The price target for WalkMe is set to $23.00. The current stock performance of WalkMe shows a 52-week-high of $34.42 and a 52-week-low of $11.50. Moreover, at the end of the last trading period, the closing price was at $14.92.
    • With a Buy rating, Goldman Sachs initiated coverage on Appian Corp (NASDAQ:APPN). The price target seems to have been set at $70.00 for Appian. In the fourth quarter, Appian showed an EPS of $0.16, compared to $0.03 from the year-ago quarter. The current stock performance of Appian shows a 52-week-high of $149.82 and a 52-week-low of $46.85. Moreover, at the end of the last trading period, the closing price was at $48.37.
    • With a Neutral rating, Goldman Sachs initiated coverage on Vor Biopharma Inc (NASDAQ:VOR). The price target seems to have been set at $6.00 for Vor Biopharma. For the fourth quarter, Vor Biopharma had an EPS of $0.49, compared to year-ago quarter EPS of $55.10. At the moment, the stock has a 52-week-high of $31.20 and a 52-week-low of $5.02. Vor Biopharma closed at $5.60 at the end of the last trading period.
    • UBS initiated coverage on Cazoo Group Ltd (NYSE:CZOO) with a Neutral rating. The price target for Cazoo Gr is set to $2.60. The stock has a 52-week-high of $10.13 and a 52-week-low of $1.99. At the end of the last trading period, Cazoo Gr closed at $1.99.
    • With a Buy rating, Goldman Sachs initiated coverage on Insmed Inc (NASDAQ:INSM). The price target seems to have been set at $56.00 for Insmed. For the fourth quarter, Insmed had an EPS of $0.95, compared to year-ago quarter EPS of $1.00. The current stock performance of Insmed shows a 52-week-high of $36.97 and a 52-week-low of $20.02. Moreover, at the end of the last trading period, the closing price was at $22.22.

    See all analyst ratings initiations.

    Get the next $ACC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACC
    $ACM
    $AFIB
    $APPN

    CompanyDatePrice TargetRatingAnalyst
    Brookfield Asset Management Inc
    $BAM
    2/5/2026$58.00Market Perform → Outperform
    BMO Capital Markets
    JetBlue Airways Corporation
    $JBLU
    2/3/2026$6.00Sell → Neutral
    Citigroup
    Royalty Pharma plc
    $RPRX
    1/30/2026$49.00Neutral → Buy
    UBS
    Insmed Incorporated
    $INSM
    1/28/2026$231.00Overweight
    Barclays
    SkyWest Inc.
    $SKYW
    1/26/2026$132.00 → $122.00Buy
    TD Cowen
    Ecolab Inc.
    $ECL
    1/23/2026Buy → Hold
    Erste Group
    Insmed Incorporated
    $INSM
    1/23/2026$212.00Buy
    Roth Capital
    Carter's Inc.
    $CRI
    1/21/2026$50.00Neutral → Buy
    Citigroup
    More analyst ratings

    $ACC
    $ACM
    $AFIB
    $APPN
    SEC Filings

    View All

    Organon & Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Organon & Co. (0001821825) (Filer)

    2/12/26 7:45:44 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Halliburton Company filed SEC Form 8-K: Leadership Update

    8-K/A - HALLIBURTON CO (0000045012) (Filer)

    2/11/26 4:05:27 PM ET
    $HAL
    Oilfield Services/Equipment
    Energy

    SEC Form 10-K filed by Royalty Pharma plc

    10-K - Royalty Pharma plc (0001802768) (Filer)

    2/11/26 9:04:11 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACC
    $ACM
    $AFIB
    $APPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Robert Half Names Senior Leader to Drive Business Operations Modernization

    MENLO PARK, Calif., Feb. 12, 2026 /PRNewswire/ -- Global talent solutions and business consulting firm Robert Half (NYSE: RHI) has appointed Ryan Skubis to senior district president, business operations modernization. In this newly created role, Skubis will lead efforts to strengthen the company's operational infrastructure, advance technology adoption and accelerate strategic initiatives supporting teams and customers worldwide. Skubis joined Robert Half in 1999 and has held numerous leadership roles during his tenure. Most recently, he served as senior district president for

    2/12/26 11:15:00 AM ET
    $RHI
    Professional Services
    Consumer Discretionary

    SLB Awarded Multiple Offshore Drilling Contracts by Mubadala Energy for Tangkulo Deepwater Development in Indonesia

    Contracts support offshore gas development with first gas targeted before end of 2028 Global energy technology company SLB (NYSE:SLB) has been awarded multiple offshore drilling services contracts by Mubadala Energy, the Abu Dhabi headquartered international energy company, for the Tangkulo natural gas deepwater development and associated exploration and appraisal drilling activities in the Andaman Sea, offshore Indonesia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212809124/en/The project will leverage SLB's offshore and deepwater technologies, including real-time downhole monitoring, to reduce operational risk, improv

    2/12/26 8:00:00 AM ET
    $SLB
    Oilfield Services/Equipment
    Energy

    Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

    Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at constant currency Full year 2025 diluted earnings per share of $0.72 and non-GAAP Adjusted diluted earnings per share of $3.66 Full year 2025 Adjusted EBITDA of $1.91 billion inclusive of $6 million of IPR&D, representing a 30.7% Adjusted EBITDA margin The company expects to deliver approximately $6.2 billion of revenue and approximately $1.9 billion of Adjusted EBITDA for the full year 2026, both measures in-line with full year 2025 performance. Organon (NYSE:OGN) today announced its results for the fourth quarter and full year ended December 31, 2025. "In 2025 we took action that demonstrate

    2/12/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACC
    $ACM
    $AFIB
    $APPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Markowicz Jana bought $288,000 worth of shares (15,000 units at $19.20), increasing direct ownership by 147% to 25,176 units (SEC Form 4)

    4 - ARES CAPITAL CORP (0001287750) (Issuer)

    2/10/26 4:30:26 PM ET
    $ARCC
    Finance: Consumer Services
    Finance

    Amendment: Chief Executive Officer Schnabel Michael Kort bought $239,125 worth of shares (12,500 units at $19.13), increasing direct ownership by 45% to 40,500 units (SEC Form 4)

    4/A - ARES CAPITAL CORP (0001287750) (Issuer)

    2/9/26 9:06:38 PM ET
    $ARCC
    Finance: Consumer Services
    Finance

    CFO and Treasurer Lem Scott C bought $100,038 worth of shares (5,186 units at $19.29), increasing direct ownership by 15% to 39,463 units (SEC Form 4)

    4 - ARES CAPITAL CORP (0001287750) (Issuer)

    2/9/26 9:05:16 PM ET
    $ARCC
    Finance: Consumer Services
    Finance

    $ACC
    $ACM
    $AFIB
    $APPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcgirr David W J gifted 53,400 shares and received a gift of 53,400 shares, decreasing direct ownership by 55% to 44,323 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    2/11/26 4:43:08 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $1,979,764 worth of shares (13,396 units at $147.79), decreasing direct ownership by 0.89% to 301,185 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    2/11/26 4:42:22 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Smith Jason Drew converted options into 15,500 units of Ordinary Shares and sold $147,262 worth of Ordinary Shares (7,479 units at $19.69), increasing direct ownership by 11% to 55,588 units (SEC Form 4)

    4 - UroGen Pharma Ltd. (0001668243) (Issuer)

    2/11/26 2:54:58 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACC
    $ACM
    $AFIB
    $APPN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    6/2/23 4:38:39 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    2/13/23 4:39:32 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACC
    $ACM
    $AFIB
    $APPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brookfield Asset Mgmt upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Brookfield Asset Mgmt from Market Perform to Outperform and set a new price target of $58.00

    2/5/26 6:50:02 AM ET
    $BAM
    Other Consumer Services
    Consumer Discretionary

    JetBlue Airways upgraded by Citigroup with a new price target

    Citigroup upgraded JetBlue Airways from Sell to Neutral and set a new price target of $6.00

    2/3/26 6:50:03 AM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    Royalty Pharma upgraded by UBS with a new price target

    UBS upgraded Royalty Pharma from Neutral to Buy and set a new price target of $49.00

    1/30/26 6:41:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACC
    $ACM
    $AFIB
    $APPN
    Leadership Updates

    Live Leadership Updates

    View All

    'Blue Sky' Reaches New Altitude: JetBlue and United Begin Offering Sales Across Both Airlines

    Starting this week, customers can book Blue Sky itineraries with cash or points and miles directly through JetBlue or United—unlocking broader access and a more seamless booking experience across both airlines. JetBlue (NASDAQ:JBLU) and United Airlines (NASDAQ:UAL) today announced the roll out of the next major customer benefit from their Blue Sky collaboration: beginning this week, travelers can start to purchase eligible itineraries operated by either airline directly on JetBlue.com, United.com and each airline's mobile app. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210620738/en/Photo courtesy of JetBlue and United.

    2/10/26 2:00:00 PM ET
    $JBLU
    $UAL
    Air Freight/Delivery Services
    Consumer Discretionary

    Pebblebrook Hotel Trust Elects Nina P. Jones and Bill Bayless to Board of Trustees

    The Company also announced the adoption of a New Principles-Based Board Refreshment Framework Pebblebrook Hotel Trust (NYSE:PEB) (the "Company" or "Pebblebrook") today announced the election of Nina P. Jones and Bill Bayless to the Board of Trustees. Ms. Jones's election is effective March 1, 2026. Mr. Bayless is expected to join the Board during the fourth quarter of 2026. Ms. Jones retired from T. Rowe Price, a global investment manager with over $1 trillion in assets under management, where she most recently served as Vice President, Portfolio Manager of the U.S. Real Estate Equity Strategy. She has more than 15 years of real estate investing experience at T. Rowe Price, also serving

    2/9/26 7:00:00 AM ET
    $EQR
    $PEB
    $SPG
    Real Estate Investment Trusts
    Real Estate

    Rayonier and PotlatchDeltic Announce Closing of Merger of Equals

    Rayonier (NYSE:RYN) today announced the closing of its merger with PotlatchDeltic Corporation. The combined company owns over four million acres of geographically diverse timberland in the United States, and operates six sawmills, an industrial-grade plywood mill, residential and commercial real estate developments, and a rural land sales program. Mark McHugh, President and Chief Executive Officer of Rayonier, said, "We are excited to close this strategic merger of equals, and we are confident that combining these two exceptional land resources companies will generate meaningful value creation for our shareholders and other stakeholders." Leadership, Board Composition, and Name The se

    1/30/26 5:30:00 PM ET
    $PCH
    $RYN
    Real Estate Investment Trusts
    Real Estate

    $ACC
    $ACM
    $AFIB
    $APPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Rush Street Interactive Inc.

    SC 13D/A - Rush Street Interactive, Inc. (0001793659) (Subject)

    12/4/24 6:04:56 PM ET
    $RSI
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Rush Street Interactive Inc.

    SC 13D/A - Rush Street Interactive, Inc. (0001793659) (Subject)

    11/27/24 4:47:40 PM ET
    $RSI
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $ACC
    $ACM
    $AFIB
    $APPN
    Financials

    Live finance-specific insights

    View All

    Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

    Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at constant currency Full year 2025 diluted earnings per share of $0.72 and non-GAAP Adjusted diluted earnings per share of $3.66 Full year 2025 Adjusted EBITDA of $1.91 billion inclusive of $6 million of IPR&D, representing a 30.7% Adjusted EBITDA margin The company expects to deliver approximately $6.2 billion of revenue and approximately $1.9 billion of Adjusted EBITDA for the full year 2026, both measures in-line with full year 2025 performance. Organon (NYSE:OGN) today announced its results for the fourth quarter and full year ended December 31, 2025. "In 2025 we took action that demonstrate

    2/12/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JetBlue to Participate in Fireside Chat at Barclays 43rd Annual Industrial Select Conference

    JetBlue Airways Corporation (NASDAQ:JBLU) will participate in a fireside chat at the Barclays 43rd Annual Industrial Select Conference on February 18th, 2026 at approximately 10:25 a.m. ET. A live, listen-only webcast of the call will be available on JetBlue's investor relations website at the following web address: http://investor.jetblue.com For those unable to listen to the live webcast, it will also be archived on JetBlue's investor relations website under 'Archived Events & Presentations' following the conference call. About JetBlue JetBlue is New York's Hometown Airline®, and a leading carrier in Boston, Fort Lauderdale-Hollywood, Los Angeles, Orlando and San Juan. JetBlue c

    2/11/26 4:30:00 PM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    Royalty Pharma Reports Q4 and Full Year 2025 Results

    Portfolio Receipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025Net cash provided by operating activities of $827 million in Q4 2025 and $2,490 million for FY 2025Full year 2026 guidance: Portfolio Receipts expected to be $3,275 million to $3,425 million NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the fourth quarter and full year 2025 and introduced full year 2026 guidance for Portfolio Receipts. "We had one of the most remarkable years in Royalty Pharma's history in 2025," said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chai

    2/11/26 7:00:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care